Background and Aim: Some clinical trials have reported on the treatment of alcohol-drinking smokers with drugs. This network meta-analysis aims to explore the effect of pharmacological interventions on smoking cessation in such populations. Methods: Only randomized controlled trials (RCTs) were included through a system and comprehensive database search. The risk of bias for the included studies were assessed using Cochrane tool. A network meta-analysis was performed using STATA software to evaluate the effect size between different comparisons, and provide the best smoking cessation intervention based on the SUCRA value. Results: A total of 15 RCTs involving 1565 participants were included. The risk of bias was low in five studies and unclear in ten studies. Network meta-analysis showed that the superiority of quitting smoking was reflected in Varenicline vs Placebo (OR=4.90, 95%CI [1.77,13.55]), Varenicline vs Naltrexone (OR=3.50, 95%CI [1.13,11.06]), and Varenicline vs Bupropion (OR=3.32, 95%CI [1.03,10.74]). None of the other pairwise comparisons showed significant difference. Finally, the probability ranking results indicated that Varenicline was the most effective intervention. Conclusions: The network meta-analysis showed that compared with Naltrexone, Bupropion, and Placebo, Varenicline had obvious superiority in quitting smoking, while there was no difference in effect between other drugs. Meanwhile, we look forward to more high-quality studies to investigate the existing evidence.

Background Pharmacotherapies are widely used for smoking cessation. However, their effect on smoking cessation for people with alcohol dependence remains unclear. Objective This study aimed to explore the effects of pharmacotherapies on smoking cessation for people with alcohol dependence. Methods Five electronic databases were searched in January 2021 for randomized controlled trials (RCTs) reporting the use of pharmacotherapies to promote smoking cessation in people with alcohol dependence. The risk of bias was assessed using the Cochrane tool. RevMan version 5.3 was used to perform meta-analyses of the changes in smoking behavior, and the GRADE approach was used to assess the certainty of the evidence. Results Nine RCTs involving 908 smokers with alcohol dependence were identified. Eight RCTs were published in the United States, and one was from Canada. The risk of bias was rated as low in three studies and unclear in the remaining six. The results of the meta-analysis showed that, compared with the placebo group, Varenicline had a significant effect on short-term smoking cessation (three RCTs, OR = 6.27, 95% CI: [2.49, 15.78], p < 0.05, very low certainty). Naltrexone had no significant effect on smoking cessation in short-term or long-term observations (three RCTs, OR = 0.99, 95% CI: [0.54, 1.81], p = 0.97, moderate certainty), and Topiramate had no significant effect (two RCTs, OR = 1.56, 95% CI: [0.67, 3.46], p > 0.05, low certainty). Only one trial reported that Bupropion had no effect on smoking cessation. Conclusion Varenicline may have a positive effect on smoking cessation in people with alcohol dependence. However, Naltrexone, Topiramate, and Bupropion seem to have no clear effect on increasing smoking abstinence among drinkers. The small number of studies and the low certainty of evidence indicate that caution is required in interpreting the results.

Background: Traditional radiotherapy is difficult to carry out definite treatment without damaging the adjacent brain parenchyma. Many studies have shown that the physical properties of carbocation radiation therapy allow treatment to reduce damage to critical structures and thus improve patient survival. Purpose: The purpose of this systematic review and meta-analysis is to evaluate the efficacy and safety of Carbon ion or Carbon ion combination radiation therapy in improving meningioma. Materials and Methods: The related studies published from January 1, 1951 to August 1, 2020 were searched comprehensively on PubMed, Cochrane Library, China Biomedical Literature Database, Web of Science, EMBASE. The extracted data included studies focused on rates and types of adverse events were sorted and classified by excel, and the overall survival and local control rates data were further analyzed with R software, Results: In eight included studies and 506 individuals, the three-year survival rate and annual local control rate of benign meningiomas were 100%. The one-year, two-year and 5-year survival rates of patients with atypical meningioma were 100%, 95% and 50%. The one-year and two-year survival rates of patients with recurrent intracranial meningiomas were 90% and 71% respectively. The one-year and two-year local control rates of non-benign meningiomas were 53% and 33% respectively. Headache, sensory impairment, cognitive impairment, and hearing impairment were the most common toxic reactions, with incidences of 19.4%, 23.7%, 9.1% and 9.1%, respectively.